BC Innovations | May 17, 2019
Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

Model-informed drug development is poised to move into personalized dosing, with a little help from exosomes. An August FDA workshop aims to shed light on when and how to use these precision dosing models in...
BioCentury | Jan 27, 2018
Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier...
BioCentury | Jan 13, 2018
Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
BioCentury | Jul 28, 2017
Regulation

Ganging up in rare disease

A joint proposal from EMA and FDA that encourages companies to join multidrug platform trials for pediatric Gaucher’s disease came too late to serve its original purpose. But the proposal could provide a template for...
BC Week In Review | Jul 21, 2017
Company News

NICE final guidance recommends Sanofi's Cerdelga for Type I Gaucher's

Last month, the U.K.'s NICE issued final guidance recommending the use of Cerdelga eliglustat from the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher’s disease in adults who are cytochrome P450...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BioCentury | Jun 8, 2015
Product Development

Perennial pioneer

Genzyme Corp. aims to remain a leader in Orphan diseases by adopting clinical innovations from oncology and continuing to engage patients from early research all the way to the market to speed development, approval and...
BC Innovations | May 21, 2015
Targets & Mechanisms

Intersection in marrow

An unlikely connection between Gaucher's disease and multiple myeloma has been uncovered by a U.K. group that found a common node in the pathways responsible for the bone disease symptoms that accompany both diseases. Suppression...
BC Week In Review | Apr 6, 2015
Clinical News

Cerdelga eliglustat tartrate regulatory update

Sanofi’s Genzyme Corp. unit said Japan approved Cerdelga eliglustat to treat Type I Gaucher’s disease in adults. The ceramide analog that inhibits glucosylceramide synthase (GCS) is approved in the U.S., the EU and Australia. Sanof...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
Items per page:
1 - 10 of 60